2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°Á : 2024-03-23
±³À°ÀÏÀÚ : 2024-03-23
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£
±³À°ÁÖÁ¦ : 2024³â ´ëÇѽÉÀåÇÐȸ ºÎ¿ï°æÁöȸ Ãá°è¿¬¼ö°ÁÂ
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ºÎ¿ï°æÁöȸ
´ã´çÀÚ : »ç¹«±¹
¿¬¶ôó : 051-240-5070
À̸ÞÀÏ : sericonf@gmail.com
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í 1. »çÀüµî·Ï 30,000ÇöÀåµî·Ï 50,000 2. Æò»ýȸ¿øÀº »çÀüµî·Ïºñ ¹«·áÀÔ´Ï´Ù. Æò»ýȸ¿ø °¡ÀÔÀ» ¿øÇϽô ȸ¿øÀº 10¸¸¿ø ÀÔ±ÝÈÄ ÇÐȸ·Î ¿¬¶ôÁֽñ⠹ٶø´Ï´Ù.
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:00~09:20 Major imaging trials for coronary intervention in 2023 ÃÖÁ¤Ãµ(ºÎ»ê´ëÇб³º´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:20~09:40 How to de-escalate the antiplatelet in patients at high bleeding risk °¹Î±Ô(ÁøÁÖ°æ»ó´ëº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 09:40~10:00 Calcification: Final enemy for coronary intervention, How to deal with? ÀåÀç½Ä(ºÎ»ê¹éº´¿ø)
Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:00~10:20 Discussion ÀÌ¿ëȯ,ÇѾçõ,¼ÛÀ±¼®,¹Ú¿ëÈÖ(µ¿·¡ºÀ»ýº´¿ø,â¿øÆÄƼ¸¶º´¿ø,ÇØ¿î´ë¹éº´¿ø,â¿ø°æ»ó´ëº´¿ø)
ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:20~10:30 ½Ä»ç ()
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:30~10:50 Evaluaion and treatemnt of resistant hypertension ¼Á¤¼÷(ºÎ»ê´ë¹éº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 10:50~11:10 Obesity and GLP-1 antagonist ±è°èȯ(°æ»ó´ëº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:10~11:30 Appraoch and treatment for moderate AS ¹Ú¿ëÇö(¾ç»êºÎ»ê´ëº´¿ø)
Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:30~11:50 Discussion À̼ö¿ë,ÀåÁ¤À±,Á¶À±¼º,À¯Á¤³²(¾ç»êºÎ»ê´ëº´¿ø,â¿ø°æ»ó´ëº´¿ø.ÇØ¿î´ë¹éº´¿ø.ÇØ¿î´ë¹éº´¿ø)
ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 11:50~12:00 Break ()
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:10~12:30 A new stratetgy of lipid lowering therapy in ACS ±è¼öÈ«(ºÎ»êº¸Èƺ´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:30~12:50 ARNI for heart failure across the range of ejection fraction ÃÖÁ¤Çö(ºÎ»ê´ëº´¿ø)
Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 12:50~13:10 Discussion ±è¼º¸¸,±è¼öÇü,ÇãÁ¤È£,±è¹Î¿õ.Ȳ¼®Àç(µ¿ÀÇÀÇ·á¿ø,´ëµ¿º´¿ø,°í½Å´ëº´¿ø.â¿øÇѸ¶À½º´¿ø,ÁøÁÖ°æ»ó´ëº´¿ø)
ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:10~13:30 Break ()
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:30~13:50 AF ablation in HFrEF and HFpEF ±è±âÈÆ(ºÎ»ê¹éº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 13:50~14:10 NOAC: clinial recommendations for Asian population À¯°¡ÀÎ(â¿ø°æ»ó´ëº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 311È£ 14:10~14:30 PVC assessment and management °ûÇýºó(»ï¼ºÃ¢¿ø´ëº´¿ø)
Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 312È£ 14:30~14:50 Discussion ¹Ú¿µ¾Æ,¹ÚÁ¾¼º,±èÇý¸®,ÀÓ¼ºÀÏ(ºÎ»ê¹éº´¿ø,µ¿¾Æ´ëº´¿ø,ÁøÁÖ°æ»ó´ëº´¿ø.°í½Å´ëº¹À½º´¿ø)
ÈÞ½Ä 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 313È£ 14:50~15:00 Break ()
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 314È£ 15:00~15:25 TAVR device selection: Which valve to whom ¿ÀÁØÇõ(ºÎ»ê´ëº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 315È£ 15:25~15:50 TAVR for bicuspid AV and AR ¾çÅÂÇö(ºÎ»ê¹éº´¿ø)
±³À°½Ã°£ 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 316È£ 15:50~16:20 LAA closure: When and how? ±èÁß¼±(½ÅÃ̼¼ºê¶õ½º)
Åä·Ð 03¿ù 23ÀÏ ºÎ»ê º¤½ºÄÚ Á¦1Àü½ÃÀå 317È£ 16:20~16:40 Discussion ¹Ú»ó¿ì,Á¶¿ë¶ô,À̽ÿø,ÁøÇÑ¿µ(¿ï»ê´ëº´¿ø.µ¿¾Æ´ëº´¿ø,ÇѼº´¿ø,ºÎ»ê¹éº´¿ø)